April 13th, 2016, Vancouver, B.C. – Veritas Pharma Inc. (“VRT” or the “Company”) (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP) an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy, today announced that CEO and President, Dr. Lui Franciosi will present at The Growth Capital Expo 2016 Conference alongside a panel of drug researchers and biotech executives active in the development of cannabis-derived compounds for medical use.

The Conference takes place May 3 5, 2016 at Caesars Palace in Las Vegas, Nevada. www.growthcapitalexpo.com

Dr. Franciosi will share a panel discussion titled “Breakthroughs in Applied Cannabis Therapeutics” on May 4th, 2:00pm – 2:50pm. Panel participants include Seth Yakatan, Kalytera Therapeutics; Dr. Mowgli Holmes, Phylos Bioscience; and Dr. Mark Rosenfeld, ISA Scientific. This panel of leading researchers and drug development company executives will discuss the latest discoveries of these compounds’ interactions with the human endocannabinoid system, and the implications for new drug development.

The afternoon of the general session’s second day is devoted to Opportunities and Risks in Legal Marijuana Investment. In three separate panels entrepreneurs, researchers and legal advisers working in the U.S. legal cannabis environment will discuss recent advances in cannabis therapeutics and in the analysis consumer, medical, and market data in the medical and recreational marijuana markets.  The marijuana opportunities program will kick off with a keynote address from legendary cannabis researcher and breeder Robert Connell Clarke. Clarke is one of a handful of people responsible for establishing the foundation for virtually all of the commercial cannabis strains on the market today, and led the development of the first strain commissioned by a pharmaceutical company to create a prescription medicine approved by UK, Canadian and US drug regulators. His latest project is mapping the genomes of marijuana and hemp strains collected from around the world to reveal the plant’s evolutionary family tree, and identify the genetic markers that will lead to the next generation of drug, fiber and seed strains.

The afternoon continues with a panel of drug researchers and biotech executives active in the development of cannabis-derived compounds for medical use, including recent breakthroughs in the development and application of cannabinoid-based drugs to treat neurological ailments, and as opioid substitutes in pain management. Seth Yakatan of Kalytera Therapeutics; Dr. Mowgli Holmes of Phylos Bioscience, Dr. Lui Franciosi of Veritas Pharma, and Dr. Mark Rosenfield of ISA Scientific will share their insights into the state of research into these therapies and provide a glimpse into what the near future will bring.

Veritas’ CEO, Dr. Lui Franciosi commented, “We are pleased with the invitation to participate at The Growth Capital Expo, alongside the wide variety of panel members and keynote speakers in furthering the conversation into the medicinal cannabis.”

About VERITAS Pharma Inc.

Veritas Pharma Inc. is an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy. Using a ‘lean and mean’ approach to product development, the company aims to select candidate cultivars using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both product value and shareholder return. Veritas’s scientists are an inter-disciplinary team that consists of chemists, pharmacologists, anesthetists, and clinical pharmacologists. Their focus is to use their knowledge to streamline the development of cannabis based treatments to capture considerable market share. Also through its wholly owned subsidiary, Sechelt Organic Marijuana Corp., has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations (the “MMPR“).

On behalf of the Board of Directors Veritas Pharma Inc.
“Dr. Lui Franciosi”
Dr. Lui Franciosi
Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.

Investor and Public Relations Contact

Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: [email protected]
Website: www.veritaspharmainc.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!